Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ramon E Parsons

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Journal of Medicinal Chemistry|October 5, 2022
Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant CellsXufen Yu, Jia Xu, Kaitlyn M Cahuzac, et al.
Journal of Medicinal Chemistry|February 4, 2022
Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure-Activity Relationship StudiesXufen Yu, Jia Xu, Yudao Shen, et al.
Cell Reports|May 21, 2023
AKT activation because of PTEN loss upregulates xCT via GSK3β/NRF2, leading to inhibition of ferroptosis in PTEN-mutant tumor cellsKaitlyn M Cahuzac, Abigail Lubin, Kaitlyn Bosch, et al.
Journal of Medicinal Chemistry|December 2, 2021
Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase DegradersXufen Yu, Jia Xu, Ling Xie, et al.
Oncotarget|November 1, 2014
Metformin and erlotinib synergize to inhibit basal breast cancerYing-Ka Ingar Lau, Xing Du, Vinayak Rayannavar, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|December 24, 2024
Harnessing the TAF1 Acetyltransferase for Targeted Acetylation of the Tumor Suppressor p53Md Kabir, Xiaoping Hu, Tiphaine C Martin, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 17, 2025
A tumor-selective mRNA system enables precision cancer treatmentMagdalena M Żak, Jimeen Yoo, Alberto Utrero-Rico, et al.
Molecular Cell|December 22, 2010
Identification of the Rac-GEF P-Rex1 as an essential mediator of ErbB signaling in breast cancerMaria Soledad Sosa, Cynthia Lopez-Haber, Chengfeng Yang, et al.
Frontiers in Medicine|March 17, 2022
Inpatient Administration of Alpha-1-Adrenergic Receptor Blocking Agents Reduces Mortality in Male COVID-19 PatientsShilong Li, Tomi Jun, Jonathan Tyler, et al.
JCI Insight|February 6, 2024
Differential histone acetylation and super-enhancer regulation underlie melanoma cell dedifferentiationKaren Mendelson, Tiphaine C Martin, Christie B Nguyen, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Journal of Medicinal Chemistry|October 5, 2022
Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant CellsXufen Yu, Jia Xu, Kaitlyn M Cahuzac, et al.
Journal of Medicinal Chemistry|February 4, 2022
Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure-Activity Relationship StudiesXufen Yu, Jia Xu, Yudao Shen, et al.
Cell Reports|May 21, 2023
AKT activation because of PTEN loss upregulates xCT via GSK3β/NRF2, leading to inhibition of ferroptosis in PTEN-mutant tumor cellsKaitlyn M Cahuzac, Abigail Lubin, Kaitlyn Bosch, et al.
Journal of Medicinal Chemistry|December 2, 2021
Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase DegradersXufen Yu, Jia Xu, Ling Xie, et al.
Oncotarget|November 1, 2014
Metformin and erlotinib synergize to inhibit basal breast cancerYing-Ka Ingar Lau, Xing Du, Vinayak Rayannavar, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|December 24, 2024
Harnessing the TAF1 Acetyltransferase for Targeted Acetylation of the Tumor Suppressor p53Md Kabir, Xiaoping Hu, Tiphaine C Martin, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 17, 2025
A tumor-selective mRNA system enables precision cancer treatmentMagdalena M Żak, Jimeen Yoo, Alberto Utrero-Rico, et al.
Molecular Cell|December 22, 2010
Identification of the Rac-GEF P-Rex1 as an essential mediator of ErbB signaling in breast cancerMaria Soledad Sosa, Cynthia Lopez-Haber, Chengfeng Yang, et al.
Frontiers in Medicine|March 17, 2022
Inpatient Administration of Alpha-1-Adrenergic Receptor Blocking Agents Reduces Mortality in Male COVID-19 PatientsShilong Li, Tomi Jun, Jonathan Tyler, et al.
JCI Insight|February 6, 2024
Differential histone acetylation and super-enhancer regulation underlie melanoma cell dedifferentiationKaren Mendelson, Tiphaine C Martin, Christie B Nguyen, et al.
Pageof 3